Published by the C
International I
Myel
T
oma Founda
ItionNSpG
ecial Edition: S
ASCO 2006
ThalidomideandRevlimidTMIssue
The International Myeloma Foundation (IMF) presents this special edition of CITINGS,
our premiere publication featuring the most up-to-date information on myeloma treatment,
focused on thalidomide and RevlimidTM. This special edition corresponds with the annual meeting
of the American Society of Clinical Oncology (ASCO) meeting to be held June 2-6, 2006. In
this CITINGS, we have highlighted selected thalidomide and Revlimid data presentations from
the ASCO meeting. We also provide references to the latest published journal articles on both
thalidomide and Revlimid from the first quarter of this year.
We hope that CITINGS provides a detailed and informative update of the thalidomide and
Revlimid literature, as well as assists in navigating the ASCO meeting. Please feel free to contact
the IMF at (800) 452-CURE or www.myeloma.org
Susie Novis, President, IMF
AmericanSocietyofClinicalOncologyPresentations2006
This year's ASCO conference features some very important new research in the field of myeloma
pertaining to thalidomide and lenalidomide. Please be sure to learn more about the following:
Sunday, June 4, 2006
2:00 PM 2:15 PM
n Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem
cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma.
Presenter: T. Facon
Abstract No: 1
Plenary Presentation
Monday, June 5, 2006
9:30 AM 9:45 AM
n A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus
dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma.
Presenter: S. Vincent Rajkumar, MD
Abstract No: 7517
Oral Presentation
www.myeloma.org
(800) 452 - CURE (2873)
Funded by an educational grant from Celgene Corporation.
9:45 AM 10:00 AM
n Correlation of bone marrow angiogenesis
n Oral lenalidomide plus melphalan and
and response to thalidomide dexamethasone in
prednisone (R-MP) for newly diagnosed
multiple myeloma.
multiple myeloma.
Presenter: Shaji Kumar
Presenter: Antonio Palumbo, MD
Abstract No: 7621 Poster No: Y11
Abstract No: 7518
General Poster Session
Oral Presentation
n Development of neuropathy in patients (pts)
with multiple myeloma (MM) treated with
10:45 AM 11:00 AM
thalidomide (thal) Patterns of occurrence and
n Lenalidomide plus high-dose dexamethasone
the role of electrophysiologic monitoring.
provides improved overall survival compared to
Presenter: Linda R Mileshkin, MBBS, FRACP
high-dose dexamethasone alone for relapsed or
Abstract No: 7618 Poster No: Y8
refractory multiple myeloma (MM): Results of
a North American phase III study (MM-009).
General Poster Session
Presenter: Donna M. Weber
n Lenalidomide and bortezomib induce
Abstract No: 7521
osteoclast cytotoxicity and decrease BAFF
Oral Presentation
secretion in osteoclasts in human multiple
myeloma: Clinical implications.
2:00 PM 6:00 PM
Presenter: Iris Breitkreutz
Abstract No: 7606 Poster No: X8
n Clarithromycin, lenalidomide and
dexamethasone combination therapy as
General Poster Session
primary treatment of multiple myeloma.
n Lenalidomide (Len) in combination with
Presenter: Ruben Niesvizky
dexamethasone (Dex) is more effective than
Abstract No: 7545 Poster No: 21
Dex alone at first relapse and provides better
Poster Discussion
outcomes when used early rather than as later
salvage therapy in relapsed multiple myeloma
Also, please also be aware of the following:
(MM).
Presenter: Edward A. Stadtmauer
Saturday, June 3, 2006
Abstract No: 7600 Poster No: X1
8:00 AM 12:00 PM
General Poster Session
n Bendamustine in combination with
n Thalidomide increases thrombin generation
thalidomide and prednisolone (BPT) in
in multiple myeloma patients.
patients with refractory or relapsed multiple
Presenter: Dulcinea Candelaria
myeloma: Results of a phase I clinical trial.
Abstract No: 7602 Poster No: X3
Presenter: Wolfram Poenisch
General Poster Session
Abstract No: 7620 Poster No: Y10
General Poster Session
www.myeloma.org
(800) 452 - CURE (2873)
Sunday, June 4, 2006
11:00 AM 11:15 AM
11:00
n Comparison of lenalidomide in combination
AM 11:15 AM
with dexamethasone to dexamethasone alone
n Increased risk of thrombosis with
in patients who have received prior thalidomide
lenalidomide in combination with
in relapsed or refractory multiple myeloma.
dexamethasone and erythropoietin.
Presenter: Michael Wang
Presenter: Ruben Niesvizky
Abstract No: 7522
Abstract No: 7506
Oral Presentation
Clinical Science Symposium
11:45 AM 12:00 PM
Monday, June 5, 2006
n A phase II trial of lenalidomide for patients
10:30 AM 10:45 AM
with AL amyloidosis.
n A multicenter prospective randomized
Presenter: Vaishali Sanchorawala
study testing non-inferiority of thalidomide
Abstract No: 7524
100 mg/day as compared with 400 mg/day
Oral Presentation
in patients with refractory/relapsed multiple
myeloma: Results of the final analysis of the
IFM 01-02 study.
Presenter: Ibrahim Yakoub-Agha
Abstract No: 7520
Oral Presentation
2ndQuarter2006Thalidomide
andRevlimid(lenalidomide)Publications
NBortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation
and thalidomide.
Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M,
Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C,
Greco MM, Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A.
Leuk Res. 2006 Mar;30(3):283-5. Epub 2005 Aug 18.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16111749&query_hl=1&itool=pubmed_DocSum
The authors conclude that bortezomib alone may induce high quality responses as third-line
salvage therapy with acceptable toxicity in a significant proportion of homogeneously pre-treated
myeloma patients with progressive disease after autologous transplantation and thalidomide.
www.myeloma.org
(800) 452 - CURE (2873)
NThe effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in
relapsed/refractory multiple myeloma [article in Chinese].
Gao W, An N, Chen SL.
Zhonghua Nei Ke Za Zhi (Chinese Journal of Internal Medicine). 2006 Mar;45(3):221-2. Related
Articles, Links
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16624158&itool=iconabstr&query_hl=1&itool=pubmed_DocSum
This study finds that the combination of thalidomide, cyclophosphamide, and dexamethasone is a
promising treatment regimen for relapsed/refractory multiple myeloma.
NLenalidomide plus dexamethasone effective in newly diagnosed myeloma.
Matthews K.
Nat Clin Pract Oncol. 2006 Mar;3(3):116-7.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16520782&query_hl=4&itool=pubmed_DocSum
Comment.
NStimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence
on FasL, TRAIL and their receptors on erythroblasts.
Grzasko N, Dmoszynska A, Hus M, Soroka-Wojtaszko M.
Haematologica. 2006 Mar;91(3):386-9.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16531263&query_hl=1&itool=pubmed_DocSum
The expression of proteins of the tumor necrosis factor (TNF) family on erythroblasts was
measured during thalidomide treatment in 29 patients with multiple myeloma. The study's
results suggest that thalidomide may stimulate erythropoiesis in myeloma patients by decreasing
the expression of TNF-like ligands/receptors on erythroblasts.
NThe changing landscape of myeloma therapy.
Cavo M, Baccarani M.
N Engl J Med. 2006 Mar 9;354(10):1076-8.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16525146&query_hl=1&itool=pubmed_DocSum
Editorial.
www.myeloma.org
(800) 452 - CURE (2873)
NProgress in the treatment of multiple myeloma.
Kumar S.
Lancet. 2006 Mar 11;367(9513):791-2.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16530557&query_hl=1&itool=pubmed_DocSum
Comment.
NEnhancement of ligand dependent activation of human Natural Killer T cells by
lenalidomide: therapeutic implications.
Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV.
Blood. 2006 Mar 28; [Epub ahead of print]
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16569772&query_hl=1&itool=pubmed_DocSum
This study demonstrates that lenalidomide and its analogues enhance CD1d mediated presentation
of glycolipid antigens and supports combining these agents with NKT-targeted approaches for
protection against tumors.
NAdvances in oral therapy for multiple myeloma.
Morgan GJ, Krishnan B, Jenner M, Davies FE.
Lancet Oncol. 2006 Apr;7(4):316-25.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16574547&query_hl=1&itool=pubmed_DocSum
New oral treatments that target myeloma cells or bone marrow are being developed that are
highly effective yet have low toxic effects, such as the immunomodulatory drugs thalidomide
and lenalidomide. The authors discuss the early development of these various treatments. The
availability of these oral treatments is hoped to improve regimens that, if used sequentially or
in combination, offer the potential of making multiple myeloma a chronic disease, thereby
extending patients' lifespans and improving quality of life.
www.myeloma.org
(800) 452 - CURE (2873)
NExtramedullary relapse of multiple myeloma presenting as hematemesis and melena.
Dawson MA, Polizzotto MN, Gordon A, Roberts SK, Spencer A.
Nat Clin Pract Oncol. 2006 Apr;3(4):223-226.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16596146&query_hl=1&itool=pubmed_DocSum
The authors assess a 60-year-old woman with multiple myeloma relapsed after a good partial
response to high-dose chemotherapy (melphalan 200 mg/m2) and autologous stem-cell
transplantation, followed by thalidomide and prednisolone maintenance therapy. She presented
with hematemesis and melena following salvage chemotherapy with dexamethasone,
cyclophosphamide, etoposide, cisplatin, and rescue therapy with single-agent bortezomib.
The authors diagnose the patient with multifocal extramedullary relapse of multiple myeloma
involving the stomach and duodenum and suggest management via high-dose infusion of
omeprazole, blood product support, palliative analgesics and anxiolytic agents.
NIntravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple
myeloma.
Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.
Eur J Haematol. 2006 Apr;76(4):273-7.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16519697&query_hl=1&itool=pubmed_DocSum
The authors address the feasibility and efficacy of a three-drug combination consisting of
intravenous (i.v.) melphalan, thalidomide and prednisone [M(i.v.)PT] for advanced myeloma
patients. They conclude that M(i.v.)PT is an effective regimen that can overcome resistance to
thalidomide plus prednisone in advanced myeloma with acceptable toxicity.
NLovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell
apoptosis in short-term cell cultures.
Dmoszynska A, Podhorecka M, Klimek P, Grzasko N.
Eur J Clin Pharmacol. 2006 Apr;62(4):325-9. Epub 2006 Mar 8.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16523333&query_hl=1&itool=pubmed_DocSum
The authors conclude that the mixture of lovastatin and thalidomide may increase the rate of
multiple myeloma cell apoptosis in comparison to the single drug and the precise mechanism of
this effect should be approved by further research.
www.myeloma.org
(800) 452 - CURE (2873)
NNew treatment strategy of multiple myeloma for cure [article in Japanese].
Murakami H, Handa H.
Gan To Kagaku Ryoho. 2006 Apr;33(4):417-23.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16612147&query_hl=1&itool=pubmed_DocSum
The authors address the treatment advances made in the field of multiple myeloma, including
the novel drugs (thalidomide, thalidomide/dexamethasone, lenalidomide, bortezomib) that have
been introduced in the treatment of patients with relapsed/refractory multiple myeloma, and the
improved prognosis and life span of these patients.
NThalidomide for the treatment of leptomeningeal multiple myeloma.
Yutaka H, Mariko Y, Shinichiro O, Kunihiko M, Yusuke T, Yasuo I.
Eur J Haematol. 2006 Apr;76(4):358-9
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16519710&query_hl=1&itool=pubmed_DocSum
Comment.
NThalidomide gives food for thought in multiple myeloma.
Burton A.
Lancet Oncol. 2006 Apr;7(4):283-4.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16598872&query_hl=1&itool=pubmed_DocSum
News.
NTotal therapy 2 without thalidomide in comparison with total therapy 1: role of
intensified induction and posttransplantation consolidation therapies.
Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-
Roman M, Shaughnessy J, Epstein J, Crowley J.
Blood. 2006 Apr 1;107(7):2633-8. Epub 2005 Dec 1.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16322468&query_hl=1&itool=pubmed_DocSum
The authors note that patients with myeloma, treated on the thalidomide arm of total
therapy 2 (TT2), had a higher complete response (CR) rate and improved event-free survival
(EFS) but not overall survival (OS). They therefore evaluate the benefit of TT2's posttandem
autotransplant consolidation chemotherapy and dexamethasone maintenance, and compare
outcomes on TT2 without thalidomide. The authors conclude that TT2 (without thalidomide)
improved OS of patients without cytogenetic abnormalities (CAs); those with CAs benefited
from posttransplantation consolidation chemotherapy. The favorable effects of CR and rapidly
sequenced second transplantation attest to the validity of a melphalan dose-response effect in
myeloma.
www.myeloma.org
(800) 452 - CURE (2873)
NDevelopment of multiple myeloma in a patient with chronic hepatitis C: A case report and
review of the literature.
Lakatos PL, Fekete S, Horanyi M, Fischer S, Abonyi ME.
World J Gastroenterol. 2006 Apr 14;12(14):2297-300.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16610042&query_hl=1&itool=pubmed_DocSum
The authors report a case of a 50-year-old woman with chronic hepatitis C (CHC) who has been
followed since 1998 due to a high viral load, genotype 1b and moderately elevated liver function
tests (LFTs). In March 2003, multiple myeloma (MM) was diagnosed (IgG-kappa, bone marrow
biopsy: 50% plasma cell infiltration). After six cycles of VAD therapy, the multiple myeloma
regressed. Thalidomide as a second-line treatment of refractory MM was initiated. The authors
conclude that although a pathogenic role of HCV infection in malignant lymphoproliferative
disorders has not been established, non-Hodgkins lymphoma and possibly MM may develop in
CHC patients, supporting the role of complex follow-up in these patients.
NRemarkable activity of novel agents bortezomib and thalidomide in patients not
responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell
transplantation in multiple myeloma.
van de Donk NW, Kroger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-
Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck
LF, Lokhorst HM.
Blood. 2006 Apr 15;107(8):3415-6.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16597603&query_hl=1&itool=pubmed_DocSum
Letter.
NThalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of
PU.1.
Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial
I, Mapara MY, Stirling D, Roodman D, Lentzsch S.
Blood. 2006 Apr 15;107(8):3098-105. Epub 2005 Dec 22.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16373662&query_hl=1&itool=pubmed_DocSum
This study investigates the effects of CC-4047 (an immunomodulatory analog of thalidomide) and
thalidomide on human osteoclastogenesis, using in vitro receptor activator of NFkappa-B ligand/
macrophage colony-stimulating factor-stimulated bone marrow cell cultures. Its results provide
evidence that CC-4047 blocks osteoclast differentiation during early phases of osteoclastogenesis.
Therefore, CC-4047 might be a valuable drug for targeting both tumors and osteoclastic activity
in patients with multiple myeloma and other diseases associated with osteolytic lesions.
www.myeloma.org
(800) 452 - CURE (2873)
NAmyloidosis.
Comenzo RL.
Curr Treat Options Oncol. 2006 May;7(3):225-36.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16615878&query_hl=1&itool=pubmed_DocSum
The author discusses amyloidosis, a disease in which abnormal proteins that form fibrillar tissue
deposits can compromise key viscera and lead to early death. In order to treat amyloidosis, the type
of abnormal protein must be identified. Drugs effective in multiple myeloma are usually helpful in
AL amyloidosis if tolerated. The use of novel antibody-based approaches for imaging amyloid and
possibly for accelerating removal of deposits is under active investigation.
NBisphosphonates may potentiate effects of thalidomide-dexamethasone combination in
advanced multiple myeloma.
Ural AU, Avcu F.
Am J Hematol. 2006 May;81(5):385-6.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16628715&query_hl=1&itool=pubmed_DocSum
Comment.
NBortezomib: an effective agent in extramedullary disease in multiple myeloma.
Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blade J, Montserrat E.
Eur J Haematol. 2006 May;76(5):405-8. Epub 2006 Mar 9.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16529604&query_hl=1&itool=pubmed_DocSum
The authors address the lack of information on the effect of bortezomib on extramedullary
myeloma. In their study, 4 of 23 patients treated with bortezomib at their institution had
extramedullary involvement at the time of relapse. In 3 of these patients, large soft-tissue
plasmacytomas disappeared, indicating that bortezomib may be useful in clinical situations
of extramedullary disease in which other agents, such as thalidomide, may not be effective.
www.myeloma.org
(800) 452 - CURE (2873)
NFirst-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone
resorption markers in patients with multiple myeloma.
Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P, Perrone G, Ceccolini M, Boni P,
Tura S, Baccarani M, Cavo M.
Eur J Haematol. 2006 May;76(5):399-404. Epub 2006 Feb 15.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16480429&query_hl=1&itool=pubmed_DocSum
This study addresses the bone involvement frequently observed in multiple myeloma patients both
at diagnosis and during the course of the disease. The evaluation of biochemical markers of bone
turnover could allow a dynamic evaluation of the effects of a given therapy on bone metabolism.
The authors conclude that among all bone resorption markers, urinary N-terminal telopeptide
of collagen I and serum crosslaps seem to be strictly related to the extent of bone involvement in
myeloma. Combined thalidomide/dexamethasone and zoledronic acid seem to be highly effective
in reducing bone resorption in sensitive patients, although the relative contribution of each drug
cannot yet be determined.
NMaintenance thalidomide following single cycle autologous peripheral blood stem cell
transplant in patients with multiple myeloma.
Sahebi F, Spielberger R, Kogut NM, Fung H, Falk PM, Parker P, Krishnan A, Rodriguez R,
Nakamura R, Nademanee A, Popplewell L, Frankel P, Ruel C, Tin R, Ilieva P, Forman SJ, Somlo G.
Bone Marrow Transplant. 2006 May;37(9):825-9.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16565743&query_hl=1&itool=pubmed_DocSum
This study concludes that thalidomide as maintenance therapy is feasible and may improve
outcome after single autologous stem cell transplant.
NNeurologic toxicities of cancer therapies.
Cavaliere R, Schiff D.
Curr Neurol Neurosci Rep. 2006 May;6(3):218-26.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16635431&query_hl=1&itool=pubmed_DocSum
The authors discuss neurologic dysfunction as a well-recognized adverse effect of cancer
therapeutics. Their review focuses on the clinical features, mechanisms, and possible therapeutics
of the neurotoxicity of chemotherapy, including thalidomide.
www.myeloma.org
(800) 452 - CURE (2873)
NNovel treatment approaches for patients with relapsed and refractory multiple myeloma.
Sinha R, Lonial S.
Curr Treat Options Oncol. 2006 May;7(3):246-57.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16615880&query_hl=1&itool=pubmed_DocSum
The authors address the newly developing treatment options for patients with relapsed myeloma.
They note that the next generation of novel agents targeting heat shock proteins, the mitogen-
activated protein kinase pathway, and monoclonal antibodies are further expanding the list of
future potential agents and that the rapid clinical development of targeting agents will allow for
more options to treat patients with relapsed or refractory myeloma, thereby improving quality of
life and overall survival.
NSmoldering multiple myeloma and monoclonal gammopathy of undetermined
significance.
Blade J, Rosinol L.
Curr Treat Options Oncol. 2006 May;7(3):237-45.
Related Articles, Links
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16615879&query_hl=1&itool=pubmed_DocSum
The authors discuss special cases of smoldering multiple myeloma (SMM) and monoclonal
gammopathy of undetermined significance (MGUS).
NMaintenance therapy with thalidomide improves overall survival after autologous
hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT, Waller EK, Leong T, Heffner LT Jr, Redei I, Langston AA, Lonial S.
Cancer. 2006 May 15;106(10):2171-80.
:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list
_uids=16598756&query_hl=1&itool=pubmed_DocSum
The authors review 112 patients with multiple myeloma who received autologous hematopoietic
progenitor cell (HPC) grafts at their institution and conclude that combination chemotherapy
provided no advantage over high-dose melphalan in patients with myeloma who underwent
autologous HPC transplantation. The authors also noted that the post-transplantation use of
thalidomide seemed to improve the survival of patients compared with historical controls from the
pre-thalidomide era. Further prospective trials are underway to confirm the benefit of thalidomide
in the post-transplantation setting.
www.myeloma.org
(800) 452 - CURE (2873)
(800)452-CURE(2873)
www.myeloma.org
www.myeloma.org
(800) 452 - CURE (2873)